
Aptorum Group Limited (NASDAQ:APM) stock is trading higher on Thursday, with a robust session volume of 168.16 million compared to the average volume of 3.25 million, as per data from Benzinga Pro.
Its merger partner, DiamiR Biosciences Corp., received a Clinical Laboratory Evaluation Program (CLEP) Test Approval for its APOE Genotyping test from the New York State Department of Health (NYSDOH).